Nottingham Advisors buys $1,192,376 stake in Ocular Therapeutix Inc (OCUL)

Ocular Therapeutix Inc (OCUL) : Nottingham Advisors scooped up 7,000 additional shares in Ocular Therapeutix Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 189,266 shares of Ocular Therapeutix Inc which is valued at $1,192,376.Ocular Therapeutix Inc makes up approximately 0.21% of Nottingham Advisors’s portfolio.

Other Hedge Funds, Including , Dekabank Deutsche Girozentrale sold out all of its stake in OCUL during the most recent quarter. The investment firm sold 10,000 shares of OCUL which is valued $64,700.Great West Life Assurance Co Can reduced its stake in OCUL by selling 10,000 shares or 61.93% in the most recent quarter. The Hedge Fund company now holds 6,146 shares of OCUL which is valued at $25,813.Columbus Circle Investors boosted its stake in OCUL in the latest quarter, The investment management firm added 90,283 additional shares and now holds a total of 278,785 shares of Ocular Therapeutix Inc which is valued at $1,170,897. Ocular Therapeutix Inc makes up approx 0.01% of Columbus Circle Investors’s portfolio.Alps Advisors Inc boosted its stake in OCUL in the latest quarter, The investment management firm added 6,976 additional shares and now holds a total of 34,792 shares of Ocular Therapeutix Inc which is valued at $161,783.

Ocular Therapeutix Inc opened for trading at $7.17 and hit $8.23 on the upside on Monday, eventually ending the session at $8.21, with a gain of 21.09% or 1.43 points. The heightened volatility saw the trading volume jump to 53,87,688 shares. Company has a market cap of $204 M.

On the company’s financial health, Ocular Therapeutix Inc reported $-0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.49. The company had revenue of $.44 million for the quarter, compared to analysts expectations of $.55 million. The company’s revenue was down -3.9 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.45 EPS.

Many Wall Street Analysts have commented on Ocular Therapeutix Inc. Ocular Therapeutix Inc was Initiated by JMP Securities to “Mkt Outperform” on Aug 11, 2016.

Ocular Therapeutix Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its hydrogel is a bioresorbable formulation of polyethylene glycol (PEG) which when constituted with water takes on a gelatinous consistency. The Company’s product pipeline includes marketed candidate ReSure Sealant and products under development such as OTX-DP OTX-TP OTX-MP and anti-VEGF hydrogel depot. The Company’s lead product candidates are OTX-DP and OTX-TP.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *